Matching slides 303,780
Current window 212,821-212,850
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

212,821-212,850 of 303,780

filter-aware
14
Synchrony Financial | Results Presentation Deck | 16 slidesSynchrony Financial | Results Presentation Deck | 16 slides · Synchrony
Conference presentation Investor relations 1 hit
15
The table reconciles GAAP figures to 'Core' figures by subtracting 'Gap and BP' components.Synchrony Financial | Results Presentation Deck | 16 slides · Synchrony
Conference presentation Investor relations 1 hit
16
The table reconciles GAAP figures to CECL fully phased-in figures for capital and risk-weighted assets.Synchrony Financial | Results Presentation Deck | 16 slides · Synchrony
Conference presentation Investor relations 1 hit
01
Slide 1
Theravance Biopharma | Investor Conference Presentation Deck | 32 slidesTheravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
02
Theravance Biopharma | Investor Conference Presentation Deck | 32 slidesTheravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
03
Theravance Biopharma | Investor Conference Presentation Deck | 32 slidesTheravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Key MessagesLoop · Quick Win Big Bet1 hit
04
The slide uses a three-column layout to categorize targets by product and financial performance.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Key MessagesLoop · Quick Win Big Bet1 hit
06
The slide uses two bar charts to demonstrate growth trends in both financial and operational metrics.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations Beat · KPI Overview1 hit
08
The slide uses a timeline-based study design diagram.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
09
Theravance Biopharma | Investor Conference Presentation Deck | 32 slidesTheravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
The slide uses a funnel-like logic to arrive at the addressable population, followed by a competitive comparison table.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
Includes a forest plot showing LS Mean (95% CI) for various OHQ questionnaire scores.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The slide outlines a randomized withdrawal study design for a clinical trial.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
13
The slide features a photo of an elderly couple on a bridge, the study logo, and the company logo.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
14
Theravance Biopharma | Investor Conference Presentation Deck | 32 slidesTheravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
15
Theravance Biopharma | Investor Conference Presentation Deck | 32 slidesTheravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
17
The table displays specific financial projections for milestones and royalties between 2023 and 2026.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
19
Theravance Biopharma | Investor Conference Presentation Deck | 32 slidesTheravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
20
Includes a footnote defining OATP.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
21
Includes footnote regarding market research methodology and definitions.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
22
Theravance Biopharma | Investor Conference Presentation Deck | 32 slidesTheravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
23
Theravance Biopharma | Investor Conference Presentation Deck | 32 slidesTheravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
24
Theravance Biopharma | Investor Conference Presentation Deck | 32 slidesTheravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
25
The slide uses a three-column layout to categorize achievements into product, clinical, and financial pillars.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
26
Includes abbreviations for COPD, nOH, and PTE in the footer.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
28
The slide serves as a reference or bibliography page for clinical study presentations.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
29
The slide uses a before-after framework to justify a strategic pivot in clinical trial focus.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
30
Includes a detailed table for Trelegy Ellipta milestones and royalty projections.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
32
Includes cash position note and footnotes regarding share-based compensation.Theravance Biopharma | Investor Conference Presentation Deck | 32 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Financials1 hit
02
thredUP | Investor Presentation Deck | 33 slidesthredUP | Investor Presentation Deck | 33 slides · thredUP
Pitch deck Investor relations 1 hit